Alamar Biosciences Inc., a medical device company specializing in protein biomarker detection for disease diagnosis, successfully completed an initial public offering (IPO) that raised $191 million. The offering, which was oversubscribed, priced at the top of its marketed range, signaling strong investor demand. This move positions the company to accelerate development of its diagnostic technologies, which use blood-based biomarkers to identify conditions like cancer and autoimmune diseases.

The IPO underscores growing investor confidence in precision medicine and non-invasive diagnostic solutions.